THEOPHYLLINE CURRENT THOUGHTS ON THE RISKS AND BENEFITS OF ITS USE IN ASTHMA

被引：18

作者：

NASSER, SSM ^{[1
]}

REES, PJ ^{[1
]}

机构：

[1] GUYS HOSP,CLIN CLASSROOM,4TH FLOOR,HUNTS HOUSE,ST THOMAS ST,LONDON SE1 9RT,ENGLAND

来源：

DRUG SAFETY | 1993年 / 8卷 / 01期

关键词：

D O I：

10.2165/00002018-199308010-00003

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Theophylline and its derivatives have been used in the treatment of asthma for over 50 years, but since the advent of more potent bronchodilators their use has become cloaked in controversy. Their continued existence results from their undoubted usefulness in severe acute asthma, nocturnal asthma, childhood asthma and moderate to severe chronic airflow limitation, and because of habitual use by physicians in other situations. The precise mechanism of action of theophylline remains uncertain. The role of phosphodiesterase inhibition and adenosine antagonism has been reviewed and the clinical significance of the anti-inflammatory action of theophylline discussed. Theophylline has unpredictable metabolism when first administered, and continued monitoring of drug concentrations is essential. Commonly encountered adverse effects may occur at therapeutic serum concentrations, frequently necessitating drug withdrawal. The overlapping therapeutic and toxic theophylline serum ranges can lead to life-threatening adverse effects at the upper end of the therapeutic range, especially in the elderly in whom special precaution is required.

引用

页码：12 / 18

页数：7

共 65 条

[1] Arkinstall W.W., Review of the North American experience with evening administration of Uniphyl tablets, a once-daily dosing in the evening versus conventional twice-daily dosing, American Review of Respiratory Disease, 85, pp. 60-63, (1985)
[2] Aubier M., De Troyer A., Sampson M., Macklem P.T., Roussos C., Aminophylline improves diaphragmatic contractility, New England Journal of Medicine, 305, pp. 249-252, (1981)
[3] Aubier M., Levy J., Clerici C., Neukirch F., Cabreres F., Et al., Protective effect of theophylline on bronchial hyperresponsiveness in patients with allergic rhinitis, American Review of Respiratory Disease, 143, pp. 346-350, (1991)
[4] Barnes P.J., Greening A.P., Neville L., Timmers J., Poole G.W., Single-dose slow-release aminophylline at night prevents nocturnal asthma, Lancet, 1, pp. 299-301, (1982)
[5] Bittar G., Friedman H.S., The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants, Chest, 99, pp. 1415-1420, (1991)
[6] Blanchard J., Harvey S., Morgan W.J., Serum/saliva correlations for theophylline in asthmatics, Journal of Clinical Pharmacology, 31, pp. 565-570, (1991)
[7] Boushey H.A., Holtxman M.J., Shelley J.R., Nadel J.A., Bronchial hyperreactivity, American Review of Respiratory Disease, 121, pp. 389-413, (1980)
[8] Bowton D.L., Haddon S., Prough D.S., Adair N., Alford P.T., Et al., Theophylline effect on the cerebral blood flow response to hypoxaemia, Chest, 94, pp. 371-375, (1988)
[9] Bruguerolle B., Toumi M., Faraj F., Bervloer D., Razzouk H., Influence of the menstrual cycle on theophylline pharmacokinetics in asthmatics, European Journal of Clinical Pharmacology, 39, pp. 59-61, (1990)
[10] Calhoun W.J., Bush R.K., Enhanced reactive oxygen species metabolism of airspace cells and airway inflammation follow antigen challenge in human asthma, Journal of Allergy and Clinical Immunology, 86, pp. 306-313, (1990)

← 1 2 3 4 5 6 7 →